Premium
EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial
Author(s) -
Taghavi Ardakani Abbas,
Farrehi Maryam,
Sharif Mohammad Reza,
Ostadmohammadi Vahidreza,
Mirhosseini Naghmeh,
Kheirkhah Davood,
Moosavi Seyed Gholam Abbas,
Behnejad Milad,
Reiter Russel J.,
Asemi Zatollah
Publication year - 2018
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1111/pai.12978
Subject(s) - medicine , scorad , melatonin , atopic dermatitis , placebo , pittsburgh sleep quality index , randomized controlled trial , quality of life (healthcare) , severity of illness , dermatology life quality index , gastroenterology , disease , sleep quality , immunology , pharmacology , pathology , insomnia , alternative medicine , nursing
Background The aim of this clinical trial was to determine the effects of melatonin administration on disease severity and sleep quality in children diagnosed with atopic dermatitis ( AD ). Methods This randomized, double‐blinded, placebo‐controlled trial was conducted by recruiting 70 patients, aged 6‐12 years, who had been diagnosed with AD . Study participants were randomly allocated into two intervention groups to receive either 6 mg/d melatonin supplements or placebo (n = 35 each group) for 6 weeks. Severity of disease was assessed using the scoring atopic dermatitis ( SCORAD ) and objective SCORAD indices. Sleep quality was evaluated by completing the Children's Sleep Habits Questionnaire ( CSHQ ). Results Following 6 weeks of intervention, melatonin supplementation significantly improved SCORAD index (β −3.55; 95% CI , −6.11, −0.98; P = 0.007), objective SCORAD index (β −3.23; 95% CI , −5.08, −1.38; P = 0.001), serum total IgE levels (β −153.94 ku/L; 95% CI , −260.39, −47.49; P = 0.005), and CSHQ scores (β −2.55; 95% CI , −4.34, −0.75; P = 0.006). However, melatonin had no significant impact on pruritus scores, high‐sensitivity C‐reactive protein (hs‐ CRP ), sleep‐onset latency, total sleep time, weight, and BMI compared with placebo. Conclusions Overall, melatonin supplementation had beneficial effects on disease severity, serum total IgE levels, and CSHQ among children diagnosed with AD .